Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Jianpi Yangzheng Xiaozheng formula is a Traditional Chinese Medicine (TCM) herbal composition developed by the Affiliated Hospital of Nanjing University of Traditional Chinese Medicine (Jiangsu Province Hospital of TCM) specifically for the treatment of gastric cancer. The formula is designed based on the TCM principles of strengthening the spleen (Jianpi), nourishing vital energy (Yangzheng), and resolving masses (Xiaozheng) to combat tumor progression. It is frequently utilized as an adjuvant therapy to enhance the efficacy of conventional chemotherapy, reduce treatment-related toxicity, and improve the overall survival and quality of life for patients with advanced gastric cancer. Mechanistically, the formula exerts anti-tumor effects by inhibiting the PI3K/Akt/mTOR and Wnt/beta-catenin signaling pathways, suppressing epithelial-mesenchymal transition (EMT), and modulating the tumor immune microenvironment to enhance T-cell activity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on jianpi yangzhengxiaozheng formula.